Biology of Blood and Marrow Transplantation
Volume 9, Issue 10 , Pages 610-615 , October 2003

National marrow donor program HLA-matching guidelines for unrelated marrow transplants

  • Carolyn Katovich Hurley

      Affiliations

    • Department of Oncology, Georgetown University, Washington, DC, USA
    • ,
  • Lee Ann Baxter Lowe

      Affiliations

    • Department of Surgery, University of California, San Francisco, California, USA
    • ,
  • Brent Logan

      Affiliations

    • IBMTR/ABMTR Statistical Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    • ,
  • Chatchada Karanes

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota, USA
    • ,
  • Claudio Anasetti

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    • ,
  • Daniel Weisdorf

      Affiliations

    • National Marrow Donor Program, Minneapolis, Minnesota, USA
    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    • ,
  • Dennis L Confer

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: Dennis Confer, MD, National Marrow Donor Program, 3001 Broadway St. N.E., Minneapolis, MN 55413, USA
    • National Marrow Donor Program, Minneapolis, Minnesota, USA

Received 21 August 2003 ,Accepted 25 August 2003.

References 

  1. Morishima Y, Sasazuki T, Inoki H, et al.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–4206
  2. Sasazuki T, Juji T, Morishima Y, et al.  Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339:1177–1185
  3. Petersdorf EW, Gooley TA, Anasetti C, et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515–3520
  4. Petersdorf EW, Gooley T, Malkki M, et al.  The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol. 2001;112:988–994
  5. Petersdorf EW, Hansen JA, Martin PJ, et al.  Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345:1794–1800
  6. Flomenberg N, Baxter-Lowe LA, Confer DL, et al.  Impact of HLA-class I and class II high resolution matching on outcomes of unrelated donor BMT. Blood. 2001;98:813a; (abstr.)
  7. Hansen JA, Yamamoto K, Petersdorf E, Sasazuki T. The role of HLA matching in hematopoietic cell transplantation. Rev Immunogenet. 1999;1:359–373
  8. Kollman C, Howe CW, Anasetti C, et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors (the effect of donor age). Blood. 2001;98:2043–2051
  9. Anasetti C, Amos D, Beatty PG, et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204
  10. Ottinger HD, Rebmann V, Pfeiffer KA, et al.  Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation. 2002;73:1280–1285
  11. Wade JA, Takemoto SK, Thompson J, et al.  No deleterious effect of HLA-mismatching outside cross reactive groups (CREG) compared to within CREG mismatches following unrelated donor bone marrow transplant. Biol Blood Marrow Transplant. 2001;7:96
  12. Wade JA, Hurley CK, Takemoto SK, et al. HLA mismatching within or outside of cross reactive groups (CREG) is associated with similar outcomes after unrelated donor bone marrow transplant. Blood. In press.
  13. Wagner JE, Barker JN, DeFor T, et al.  Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases (influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival). Blood. 2002;100:1611–1618
  14. Rubinstein P, Carrier C, Scaradavou A, et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–1577
  15. Wagner JE, Thompson JS, Carter S, Jensen L, Kernan NA. Impact of graft-versus-host disease (GVHD) prophylaxis on 3-year disease-free survival (DFS) (results of a multi-center, randomized phase II-III trial comparing T cell depletion/cyclosporine (TCD) and methotrexate/cyclosporine (M/C) in 410 recipients of unrelated donor bone marrow (BM)). Blood. 2002;100:75a
  16. Ruggeri L, Capanni M, Urgani E, et al.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  17. Giebel S, Locatelli FW, Lamparelli T, et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819
  18. Davies SM, Ruggeri L, DeFor T, et al.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood. 2002;100:3825–3827

PII: S1083-8791(03)00329-X

doi: 10.1016/j.bbmt.2003.08.009

Biology of Blood and Marrow Transplantation
Volume 9, Issue 10 , Pages 610-615 , October 2003

Article Tools